SCHEMBL5136901

SCHEMBL5136901

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.42
CRHR1 P34998 3/20 0.39
CASR P41180 1/20 0.38
MDM2 Q00987 4/20 0.38
CFTR P13569 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HSD11B1 P28845 1/20 0.37
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135363 0.94 C5AR1 (0.44) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL5136579 0.94 C5AR1 (0.44) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL652310 0.92 C5AR1 (0.42) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL5137466 0.92 DHFR (0.42) C5AR1KDM4EALDH1A1TSHRHSD17B10
SCHEMBL5137538 0.92 C5AR1 (0.46) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL651094 0.91 TSHR (0.50) C5AR1KDM4EALDH1A1TSHRHPGD
SCHEMBL650105 0.91 C5AR1 (0.46) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL5137404 0.91 CRHR1 (0.43) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL651500 0.91 C5AR1 (0.43) C5AR1KDM4EALDH1A1TSHRCRHR1
SCHEMBL5135922 0.90 C5AR1 (0.49) C5AR1KDM4EALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed